http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022050609-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f71d4ef17ab7896f2df46a7001b16c79 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2013-00472 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2400-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-604 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F13-00991 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L15-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L17-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F13-00012 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F13-00063 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L15-44 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L17-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L15-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L15-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F13-00 |
| filingDate | 2021-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a01c83aecd13a7c7061435bd0c6e6abd |
| publicationDate | 2022-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022050609-A1 |
| titleOfInvention | Method for manufacturing medical material of which hemostasis and degradation rates are controllable, and medical material manufactured thereby |
| abstract | The present invention relates to a method for manufacturing a medical hemostatic material, and a medical material manufactured thereby, the method comprising: a pretreatment step of adjusting the pH of a natural cellulose substrate; a hemostatic agent adsorption step in which a hemostatic agent is adsorbed on the substrate having passed through the pretreatment step; a drying step in which the substrate having adsorbed the hemostatic agent is dried; a primary modification step in which the dried substrate is primarily modified using monochloroacetic acid (MCA); a secondary modification step in which the primarily modified substrate is secondarily modified using an organic acid aqueous solution; a washing step in which the secondarily modified substrate is washed; and a post-treatment step in which the pH of the substrate having passed through the washing step is adjusted, and thus the present invention is very biologically safe, and controls a degradation rate as necessary so as to be applicable to various situations. |
| priorityDate | 2020-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.